BioSpace News Archive

NysnoBio announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research to assist the advancement of the company’s lead Parkin gene replacement therapy candidate, NB001.

Corcept Therapeutics Incorporated announced topline results from a Phase 1b study evaluating its proprietary cortisol modulator, miricorilant, in patients with presumed non-alcoholic steatohepatitis.

Mineralys Therapeutics, Inc. announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease, which is expected to start enrolling patients in the second half of 2023.

Inhibikase Therapeutics, Inc. announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550, and that Inhibikase is in compliance with all applicable listing standards.

Aridis Pharmaceuticals, Inc. announced positive feedback from the European Medicines Agency on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients.

Transcat, Inc. announced that it will release its first quarter fiscal year 2024 results after the close of financial markets on Monday, July 31, 2023.

ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that the Company will host a conference call at 8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter 2023 operating results.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced it will report financial results for the second quarter of 2023 after market close on Monday, August 7, 2023.

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

Endo International plc and Premier, Inc. announced that Endo’s Par Sterile Products business will supply Pitocin® vials through Premier’s ProvideGx® and PremierProRx® programs.